학술논문
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial
Document Type
Article
Author
Döhner, H.; Weber, D.; Leis, C.; Schrade, A.; Kapp-Schwoerer, S.; Cocciardi, S.; Paschka, P.; Gaidzik, V.I.; Döhner, K.; Krzykalla, J.; Benner, A.; Fiedler, W.; Kühn, M.W.M.; Schroeder, T.; Mayer, K.; Lübbert, M.; Wattad, M.; Götze, K.; Fransecky, L.; Koller, E.; Wulf, G.; Schleicher, J.; Ringhoffer, M.; Greil, R.; Hertenstein, B.; Krauter, J.; Martens, U.M.; Nachbaur, D.; Samra, M.A.; Machherndl-Spandl, S.; Basara, N.; Bullinger, L.; Thol, F.; Heuser, M.; Ganser, A.; Saadati, M.; Schlenk, R.F.; Kühn, M.W.M.; Wattad, M.; Martens, U.M.; Gaidzik, V.I.; Schlenk, R.F.
Source
In: The Lancet Haematology . (The Lancet Haematology, July 2023, 10(7):e495-e509)
Subject
Language
English
ISSN
23523026